Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Investing Activities (2021 - 2025)

Lyra Therapeutics has reported Cash from Investing Activities over the past 5 years, most recently at -$96000.0 for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$96000.0 for Q4 2025, down 100.34% from a year ago — trailing twelve months through Dec 2025 was $36.2 million (down 54.95% YoY), and the annual figure for FY2025 was -$98000.0, down 100.12%.
  • Cash from Investing Activities for Q4 2025 was -$96000.0 at Lyra Therapeutics, down from $28.1 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for LYRA hit a ceiling of $36.2 million in Q2 2024 and a floor of -$64.9 million in Q4 2022.
  • Median Cash from Investing Activities over the past 5 years was -$96000.0 (2025), compared with a mean of -$45058.8.
  • Biggest five-year swings in Cash from Investing Activities: crashed 51551.72% in 2023 and later surged 6548.48% in 2024.
  • Lyra Therapeutics' Cash from Investing Activities stood at -$1.1 million in 2021, then plummeted by 5889.84% to -$64.9 million in 2022, then surged by 96.36% to -$2.4 million in 2023, then skyrocketed by 1292.5% to $28.1 million in 2024, then tumbled by 100.34% to -$96000.0 in 2025.
  • The last three reported values for Cash from Investing Activities were -$96000.0 (Q4 2025), $28.1 million (Q4 2024), and $8.1 million (Q3 2024) per Business Quant data.